Protective effects and mechanisms of Baicalin and octreotide on renal injury of rats with severe acute pancreatitis

Xi-Ping Zhang, Hua Tian, Yue-Hong Lai, Li Chen, Ling Zhang, Qi-Hui Cheng, Wei Yan, Yun Li, Qing-Yu Li, Qing He, Fei Wang

AIM: To investigate the protective effects and mechanisms of Baicalin and octreotide on renal injury of rats with severe acute pancreatitis (SAP).

METHODS: One hundred and eighty SD rats were randomly assigned to the model group, Baicalin-treated group, octreotide-treated group and sham operation group. The mortality, plasma endotoxin level, contents of IL-6, ET-1, TNF-α, IL-6 and endothelin-1 (ET-1) in serum, expression levels of renal Bax and Bcl-2 protein, apoptotic indexes and pathological changes of kidney were observed at 3, 6 and 12 h after operation.

RESULTS: The renal pathological changes were milder in treated group than in model group. The survival at 12 h and renal apoptotic indexes at 6 h were significantly ($P < 0.05$) higher in treated group than in model group [66.67% vs 100%; 0.00 (0.02)% and 0.00 (0.04)% vs 0.00 (0.00)%, respectively]. The serum CREA content was markedly lower in octreotide-treated group than in model group at 3 h and 6 h ($P < 0.01$, 29.200 ± 5.710 μmol/L vs 38.400 ± 11.344 μmol/L; $P < 0.05$, 33.533 ± 10.106 μmol/L vs 45.154 ± 17.435 μmol/L, respectively). The expression level of renal Bax protein was not significantly different between model group and treated groups at all time points. The expression level of renal Bcl-2 protein was lower in Baicalin-treated group than in model group at 6 h ($P < 0.001$, 0.00 (0.00) grade score vs 3.00 (3.00) grade score). The Bcl-2 expression level was lower in octreotide-treated group than in model group at 6 h and 12 h ($P < 0.05$, 0.00 (0.00) grade score vs 3.00 (3.00) grade score; 0.00 (0.00) grade score vs 0.00 (1.25) grade score, respectively). The serum NO contents were lower in treated groups than in model group at 3 h and 12 h ($P < 0.05$, 57.50 (22.50) and 52.50 (15.00) μmol/L vs 65.00 (7.50) μmol/L; $P < 0.01$, 57.50 (27.50) and 45.00 (12.50) μmol/L vs 74.10 (26.15) μmol/L, respectively). The plasma endotoxin content and serum BUN content (at 6 h and 12 h) were lower in treated groups than in model group. The contents of IL-6, ET-1, TNF-α (at 6 h) and PLAC (at 6 h and 12 h) were lower in treated groups than in model group ($P < 0.001$, 3.031 (0.870) and 2.646 (1.373) pg/mL vs 5.437 (1.025) pg/mL; 2.882 (1.392) and 3.076 (1.205) pg/mL vs 6.817 (0.810) pg/mL; 2.832 (0.597) and 2.462 (1.353) pg/mL vs 5.356 (0.747) pg/mL; 16.226 (3.174) and 14.85 (5.747) pg/mL vs 25.625 (7.973) pg/mL; 18.625 (5.780) and 15.185 (1.761) pg/mL vs 24.725 (3.759) pg/mL; 65.10 (27.51) and 47.60 (16.50) pg/mL vs 92.15 (23.12) pg/mL; 67.91 ± 20.61 and 66.86 ± 22.10 U/mL, 63.13 ± 26.31 and 53.63 ± 12.28 U/mL vs 101.46 ± 14.67 and 105.33 ± 18.10 U/mL, respectively].

CONCLUSION: Both Baicalin and octreotide can protect the kidney of rats with severe acute pancreatitis. The therapeutic mechanisms of Baicalin and octreotide might be related to their inhibition of inflammatory mediators and induction of apoptosis. Baicalin might be a promising therapeutic tool for severe acute pancreatitis.

© 2007 WJG. All rights reserved.

Key words: Severe acute pancreatitis; Baicalin; Octreotide; Renal injury; Rats; Tissue microarrays


INTRODUCTION

Severe acute pancreatitis (SAP) is a fatal systemic disease featuring acute onset, serious conditions, high incidence of complications and 20%-30% of mortality mainly due to multiple organ failure at its early stage[1-4]. Octreotide has been shown to exert its therapeutic effects on SAP mainly via inhibiting pancreatin secretion, release of inflammatory mediators and platelet aggregation, and reducing endotoxin generation[5-8]. It is found to improve prognosis and lower mortality by enhancing the kidney protection during SAP. Baical skullcap root is an essential of “Qingyitang”, a representative prescription of Traditional Chinese Medicine for SAP. Baicalin is its main effective ingredient (monomer). The in vitro experiment of Baicalin has confirmed it has anti-bacterial, antiviral and anti-inflammatory activities. It also can inhibit platelet aggregation and eliminate oxygen-free radicals. It was found in animal experiments that Baicalin could reduce the generation of endotoxin. In addition, Baicalein, which is the initial metabolite of Baicalin, has potent effect in inhibiting pancreatin. All these pharmacologic actions can inhibit SAP during its multiple stages[9]. It is difficult to popularize octreotide especially in remote areas with poor economy since it features high price, short half-life and inconvenient administration, while Baicalin features low price, extensive routes of administration and preparation, multiple pharmacologic actions and precise therapeutic effects.

The idea of Baicalin treatment of pancreatitis was brought forward in 1999 and validated in 2000. At the beginning, the one-time Baicalin injection via vena dorsalis penis or vena femorals injection was applied, which resulted in poor therapeutic effects. Later, it was found one-time injection was inappropriate due to the short half-life of Baicalin. The expected therapeutic effects could hardly be met with one-time injection. In 2001, the intravenous drip and large dosage were applied, which resulted in sound therapeutic effects. The idea was originated from the study of the principal on pancreatitis treated by Baicalin injection. Baicalin is hydrolyzed into Baicalein. The stability, solubility and therapeutic effects of Baicalin injection are all superior to those of Baicalin injection. In this experiment, the feasibility of Baicalin treatment for SAP has been studied by comparing the protective effects and mechanisms of Baicalin and octreotide on kidneys of rats with SAP.

MATERIALS AND METHODS

Experimental animals

Clean grade healthy male Sprague-Dawley (SD) rat, weighing 250-300 g, were purchased from the Experimental Animal Center of Medical School of Zhejiang University, China.

Experimental reagents

Sodium taurocholate and sodium pentobarbitol were purchased from USA Sigma Company. Octreotide was purchased from Swiss Pharmaceutical Company Novartis, and 5% Baicalin injection (China National Invention Patent Number ZL200310122673.6) was prepared by the first author at 305 mmol/L osmotic pressure. Plasma endotoxin tachypleus amebocyte lysate kit was purchased from Shanghai Yihua Medical Science and Technology Corporation (Institute of Medical Analysis, Shanghai, China); the calculation unit for content is EU/mL. Serum nitrogen monoxide (NO) was purchased from Nanjing Jiancheng Bioengineering Research Institute; the calculation units for content is μmol/L. TNF-α ELISA kit was purchased from Xingmei Bioengineering Corporation; the calculation unit for content is pg/mL (ng/L). IL-6 ELISA kit was purchased from Shanghai Shenxiong Biotech Company (China); the calculation unit for content is pg/mL (ng/L). Serum secretory phospholipase A2 enzyme Assay ELA kit (PLA2) was purchased from R&D system Ins; the calculation unit for content is U/mL. The serum endothelin-1 ELA kit (ET-1) was purchased from Cayman Chemical Company (Catalog Number: 583151), the calculation unit for content is ng/L (pg/mL). The Bax and Bel-2 antibodies were purchased from Santa Cruz Company, USA. The main reagents for DNA in situ nick end-labeling (TUNEL) staining (Takara In Situ Apoptosis Detection Kit) was purchased from TaKaRa Biotechnology (Dalian) Co., Ltd. PK (protease K) was purchased from Sigma Company (USA). DAB (biphenylidiamine) was purchased from China Hua-mei Company, China.

Preparation of animal models

The improved Aho’s method[10] was adopted to prepare 135 SAP rat models via retrograde injection of 35 g/L sodium taurocholate to the pancreatic duct through epidural catheter and duodenal papilla. The 135 SAP rat models were randomly assigned to the model group, Baicalin-treated group and octreotide-treated group, 45 rats in each group, while other 45 rats were assigned to the sham operation group (SO group). In sham operation group, only exploratory laparotomy (i.e., entering abdominal cavity, checking the pancreas and duodenum and then abdomen closure) was performed. Thereafter, the above-mentioned groups were randomly subdivided into 3-h, 6-h and 12-h groups, 15 rats in each group. The rats were observed at 3, 6 and 12 h after operation for: (1) Mortalities of rats in all groups followed by execution of rats and observation of gross pathological changes of kidney; (2) Kidney tissue samples were collected, fixed in accordance with relevant requirements and observed for the pathological score changes of kidney under HE staining; (3) Tissue microarray was applied to prepare the tissue microarray sections (2 mm in diameter) and immunostained using SP (streptavidin-peroxidase) method. Expressions of Bax and Bel-2 protein in the kidney tissue were observed under light microscope, and grading was carried out based on the percentage of positive cells as follows: (+) = positive
cell count < 10%, (+) = positive cell count 10%-20%,
(++) = positive cell count 20%-50%, and (++++) = posi-
tive cell count > 50% (4) TUNEL staining technique was
applied to detect apoptotic cells in the kidney and then
apoptotic index was calculated as follows: Apoptotic index
= apoptotic cell count/total cell count × 100% (5) The
changes in blood urea nitrogen (BUN), creatinine (CREA),
phospholipase A2 (PLA2), nitrogen monoxide (NO), tumor
carcinoma factor (TNF-α), IL-6 and endothelin-1 (ET-1)
contents in blood samples obtained from the heart were
determined; and (6) The correlations among these indexes
were analyzed.

Procedures
Fast but water restraint was imposed on all rat groups
12 h prior to the operation. The rats were anesthetized
by intra-peritoneal injection of 20 g/L sodium pentobar-
bital (0.25 mL/100 g), laid and fixed on table, routinely
shaved, disinfected and draped. After establishing the
right external jugular vein transfusion passage by using
the microinfusion pump for continuous transfusion
(1 mL/h per 100 g), 35 g/L sodium taurocholate was
administered to prepare SAP model. To establish model
control group, through median epigastrium incision, the
bile-pancreatic duct and hepatic hilus common hepatic
duct were confirmed, the pancreas was disclosed, the duo-
denal papilla inside the duodenum duct wall was identified,
and then a No. 5 needle was used to drill a hole in the
avascular area of mesentery. After inserting a segmental
eqidural catheter into the duodenal cavity via the hole, the
bile-pancreatic duct was inserted toward the direction of
the external jugular vein, followed by continuous intravenous
administration (10 mg/h per 100 g) by microinfusion pump. Octracetide-treated group was
first injected octracetide (0.2 μg/100 g) via the external
jugular vein, followed by continuous intravenous trans-
fusion (10 mg/h per 100 g) by microinfusion pump at a transfusion speed of 0.2 μg/h per 100 g. All above-
mentioned dosages have been proved as effective dosages
in the previous preliminary experiment[10]. Both the sham
operation group and model control group were injected
normal saline of equivalent volume at the corresponding
time points after operation. The diameter of the drilling
needle is 2.0 mm.

Statistical analysis
The values were presented as mean ± SD for normal dis-
btribution variables or median and quartile range for highly
skewed variables. The significance of differences among
the four groups was analyzed using Kruskal-Wallis test
for highly skewed data and analysis of variance (ANOVA)
for normal distribution data. Multiple comparisons were
subjected to Bonfferoni correction test. Chi-square test
was used to evaluate equality of frequencies for discrete
variables. Correlations were tested using Spearman rank
correlation coefficients. A P value less than or equal to
0.05 was considered statistically significant. All statisti-
cal analyses were conducted using SPSS version 11.5 for
windows.

RESULTS
Survival rate
The mortalities of model group were 0% (0/15), 13.33% (2/15) and 33.33% (5/15) at 3, 6 and 12 h, respectively,
while those of Baicalin-treated group and octracetide-
treated group were 0% at different time points, indicating
a marked difference at 12 h (P < 0.05). The whole sham
operation group survived at different time points.

Serum BUN content
Serum BUN content was markedly higher in model group
and treated groups than in sham operation group at all
time points (P < 0.001). However, the content was not
significantly different between Baicalin- and octracetide-
treated groups at all time points. The content was lower
in Baicalin-treated group than in model group at 3 and
12 h (P < 0.05). The content was not different between
octracetide-treated group and model group at 3 h. The
content was lower in Baicalin-treated group than in
model group at 6 h (P = 0.001), lower in octracetide-
treated group than in model group (P < 0.05), and lower
in octracetide-treated group than in model group at 12 h
(P < 0.01) (Table 1).

Serum CREA content
The CREA content was significantly higher in model
group and treated groups than in sham operation group at
all time points (P < 0.001). However, no significant differ-
ence was found between Baicalin-treated group and model
group at all time points. The content was lower in octracetide-
treated group than in Baicalin-treated group at 3 h and
12 h (P < 0.01), and also lower in octracetide-treated group
than in model group at 3 h (P < 0.01) and 6 h (P < 0.05).
But no marked difference was observed between Baicalin-

www.wjgnet.com
Table 1 Comparison of different indexes level in blood [M (Q2R)]

<table>
<thead>
<tr>
<th>Groups</th>
<th>Sham operation group</th>
<th>Model group</th>
<th>Baicalin treated group</th>
<th>Octreotide treated group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endotoxin (EU/mL)</td>
<td>3 h</td>
<td>0.016 (0.003)</td>
<td>0.053 (0.029)</td>
<td>0.027 (0.005)</td>
</tr>
<tr>
<td></td>
<td>6 h</td>
<td>0.016 (0.010)</td>
<td>0.059 (0.037)</td>
<td>0.039 (0.019)</td>
</tr>
<tr>
<td></td>
<td>12 h</td>
<td>0.014 (0.015)</td>
<td>0.060 (0.022)</td>
<td>0.034 (0.015)</td>
</tr>
<tr>
<td>BUN (mmol/L)</td>
<td>3 h</td>
<td>5.310 (0.940)</td>
<td>12.050 (4.030)</td>
<td>10.530 (3.625)</td>
</tr>
<tr>
<td></td>
<td>6 h</td>
<td>5.500 (2.200)</td>
<td>17.390 (3.850)</td>
<td>12.220 (4.530)</td>
</tr>
<tr>
<td></td>
<td>12 h</td>
<td>4.860 (1.590)</td>
<td>22.270 (11.375)</td>
<td>13.720 (4.380)</td>
</tr>
<tr>
<td>NO (μmol/L)</td>
<td>3 h</td>
<td>7.500 (5.000)</td>
<td>65.000 (7.50)</td>
<td>57.500 (22.50)</td>
</tr>
<tr>
<td></td>
<td>6 h</td>
<td>7.500 (5.000)</td>
<td>62.500 (38.75)</td>
<td>47.500 (37.50)</td>
</tr>
<tr>
<td></td>
<td>12 h</td>
<td>74.100 (26.15)</td>
<td>57.500 (27.50)</td>
<td>57.500 (15.00)</td>
</tr>
<tr>
<td>TGF-α (pg/mL)</td>
<td>3 h</td>
<td>3.900 (3.200)</td>
<td>41.440 (37.72)</td>
<td>44.930 (45.84)</td>
</tr>
<tr>
<td></td>
<td>6 h</td>
<td>4.000 (1.700)</td>
<td>92.150 (23.12)</td>
<td>65.100 (27.51)</td>
</tr>
<tr>
<td></td>
<td>12 h</td>
<td>5.3000 (3.000)</td>
<td>65.020 (26.81)</td>
<td>47.600 (25.52)</td>
</tr>
<tr>
<td>IL-6 (pg/mL)</td>
<td>3 h</td>
<td>1.846 (0.346)</td>
<td>5.437 (1.025)</td>
<td>3.031 (0.870)</td>
</tr>
<tr>
<td></td>
<td>6 h</td>
<td>1.743 (0.838)</td>
<td>6.817 (0.810)</td>
<td>2.882 (1.392)</td>
</tr>
<tr>
<td></td>
<td>12 h</td>
<td>2.036 (0.818)</td>
<td>5.356 (0.747)</td>
<td>2.832 (0.597)</td>
</tr>
<tr>
<td>ET-1 (pg/mL)</td>
<td>3 h</td>
<td>15.290 (4.231)</td>
<td>24.745 (1.011)</td>
<td>19.635 (6.065)</td>
</tr>
<tr>
<td></td>
<td>6 h</td>
<td>16.275 (3.180)</td>
<td>25.625 (7.973)</td>
<td>16.226 (3.174)</td>
</tr>
<tr>
<td></td>
<td>12 h</td>
<td>14.173 (2.556)</td>
<td>24.725 (3.759)</td>
<td>18.625 (5.780)</td>
</tr>
</tbody>
</table>

Table 2 Comparison of serum CREA content (mean ± SD, μmol/L)

<table>
<thead>
<tr>
<th>Groups</th>
<th>3 h</th>
<th>6 h</th>
<th>12 h</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham operation group</td>
<td>17.867 ± 2.890</td>
<td>21.467 ± 3.044</td>
<td>19.733 ± 3.150</td>
</tr>
<tr>
<td>Model group</td>
<td>38.400 ± 11.344</td>
<td>45.154 ± 17.435</td>
<td>41.500 ± 12.122</td>
</tr>
<tr>
<td>Octreotide-treated group</td>
<td>29.200 ± 5.710</td>
<td>33.533 ± 10.106</td>
<td>33.933 ± 9.145</td>
</tr>
</tbody>
</table>

and octreotide-treated groups. Moreover, the content was not different between octreotide-treated group and model group at 12 h (Table 2).

Gross changes and light microscopic changes of kidney

Sham operation group: Macroscopically, the morphous of kidney was normal without swelling, with no bleeding points on surface of renal cortex. Microscopically, there were normal structure of renal glomerulus, tubule and interstitium in most rats without visible pathological change; however, swelling and blurry boundary of renal tubular epithelial cells, and stenosis of lumens were found in very few rats.

Model group: Macroscopically, there was no gross change in the kidney at 3 h; but kidney swelling, tension of renal envelope, scattered bleeding points on surface of renal envelope, and slightly hemorrhagic urine in pelvis in severe cases at 6 h and 12 h. Microscopically, there were capillary congestion of renal glomerulus, swelling, scattered necrosis and blurry boundary of renal tubule epithelial cell, stenosis or atresia of lumens, visible protein cast (Figure 1A), interstitial edema and inflammatory cell infiltration at 3 h; and capillary congestion of renal glomerulus, swelling and scattered necrosis of epithelial cell of renal tubule (Figure 1B), interstitial edema (Figure 1C) and inflammatory cell infiltration at 6 and 12 h. The floss and red cell with eosinophilic staining were found in renal glomerulus and homogenous or red cell cast with eosinophilic staining in renal tubule (Figure 1D).

There was lamellar necrosis of epithelial cell of renal tubule in few rats.

Baicalin- and octreotide-treated groups: Macroscopically, the gross renal pathological changes were milder in Baicalin- and octreotide-treated group than in model group at 6 h and 12 h. Microscopically, there were less capillary congestion of renal glomerulus, swelling of renal tubular epithelial cell, floss and red cell with eosinophilic staining in renal capsule and inflammatory cell infiltration in treated group than in model group. Mild red cell cast was found occasionally in renal tubule of treated group. There were also renal interstitial edema and scattered necrosis of renal tubular epithelial cell in few cases. There was no visible difference between Baicalin- and octreotide-treated groups. Better therapeutic effects were achieved in octreotide-treated group.

Changes of pathological score of kidney in all groups

Pathological grading of kidney: The pathological grading of kidney was used (Table 3) and two pathologists performed the evaluation of degree of pathological changes in pancreatic tissue in double-blind fashion.

Comparison of pathological score of kidney: The score was significantly higher in model group, Baicalin- and octreotide-treated groups than in sham operation group at different time points (P <0.001). However, the score was lower in Baicalin- and octreotide-treated groups than in model group at 6 h (P <0.05). The score was lower in octreotide-treated group than in model group at 12 h (P <0.05). There was not significant different between Baicalin- and octreotide-treated groups at different time points (Table 4).

Expression of Bax protein in renal tissue

Bax-positive staining was located in the cytoplasm of renal tubular epithelial cell (Table 5 and Figure 2A-E). The expression level was not different among all groups at 12 h. The level was higher in model group and Baicalin-treated group than in sham operation group at 3 h and...
6 h \((P < 0.05)\), and also higher in octreotide-treated group than in sham operation group at 6 h \((P < 0.05)\). The expression level was not different between model group and Baicalin-treated group at all time points. Similarly, the expression level was not different between Baicalin- and octreotide-treated groups. The level was lower in octreotide-treated group than in model group at 3 h \((P < 0.05)\) (Table 6).

**Expression of Bcl-2 protein in renal tissue**

Bcl-2-positive staining was located in the cytoplasm of renal tubular epithelial cells. (Table 7 and Figure 3A-C). The level was higher in model group than in sham operation group at all time points \((P < 0.05)\). The level was higher in Baicalin-treated group than in sham operation group at 12 h \((P < 0.05)\), lower in octreotide-treated group than in Baicalin-treated group \((P < 0.05)\), lower in Baicalin-treated group than in model group at 6 h \((P < 0.001)\), and also lower in octreotide-treated group than in model group at 6 and 12 h \((P < 0.05)\) (Table 8).

**Comparison of renal apoptotic index**

The apoptotic cells were renal tubular epithelial cells. The index was not different between model group and sham operation group at different time points. Moreover, the index was not different among all groups at 3 and 12 h. The index was higher in Baicalin- and octreotide-treated groups than in sham operation group and model group at 6 h \((P < 0.05)\), and also different between Baicalin- and octreotide-treated groups at all time points (Table 9 and Figure 4A-D).
Comparison of plasma endotoxin content

The content was higher in model group and treated group than in sham operation group at all time points (P < 0.001). The content was not different between Baicalin- and octreotide-treated groups at 6 and 12 h. The content was lower in Baicalin- and octreotide-treated groups than in model group at 3 h (P < 0.001), lower in Baicalin-treated group than in model group at 6 h (P < 0.05), lower in octreotide-treated group than in model group at 6 h (P = 0.001), lower in Baicalin-treated group than in model group at 12 h (P < 0.001), and also lower in octreotide-treated group than in model group at 12 h (P < 0.01) (Table 1).

Comparison of serum PLA2 content

Serum PLA2 content in model group and treated groups significantly exceeded sham operation group at different time points (P < 0.001). At 3 h, PLA2 content in Baicalin-treated group was significantly less than model group and octreotide-treated group (P < 0.01), but no marked difference was observed between octreotide-treated group and model group. At 6 h and 12 h, PLA2 content in Baicalin- and octreotide-treated groups was significantly less than model group (P < 0.001). There was no marked difference between Baicalin-treated group and octreotide-treated group at 6 h, while octreotide-treated group had significantly less PLA2 content than Baicalin-treated group at 12 h (P < 0.001) (Table 10).

Comparison of serum NO content

Serum NO content in model group, Baicalin-treated group and octreotide-treated group significantly exceeded sham operation group at different time points (P < 0.001). At 3 h and 12 h, Baicalin-treated and octreotide-treated groups had significantly less serum NO content than model group (P < 0.05). There was no marked difference in serum NO content between Baicalin-treated group and octreotide-treated group at different time points (Table 1).

Table 6  Comparision of Bax protein in kidney

<table>
<thead>
<tr>
<th>Groups</th>
<th>3 h</th>
<th>6 h</th>
<th>12 h</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham operation</td>
<td>0.00 (0.00)</td>
<td>0.00 (0.00)</td>
<td>0.00 (0.00)</td>
</tr>
<tr>
<td>Model group</td>
<td>1.00 (2.00)</td>
<td>0.00 (0.50)</td>
<td>0.00 (1.25)</td>
</tr>
<tr>
<td>Baicalin-treated</td>
<td>0.00 (0.50)</td>
<td>0.00 (1.00)</td>
<td>0.00 (0.00)</td>
</tr>
<tr>
<td>Octreotide-treated</td>
<td>0.00 (0.00)</td>
<td>0.00 (1.00)</td>
<td>0.00 (1.00)</td>
</tr>
</tbody>
</table>

Table 7  Expression of Bcl-2 protein in kidney

<table>
<thead>
<tr>
<th>Groups</th>
<th>n</th>
<th>Pathologic grade</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>Sham operation</td>
<td>(3 h)</td>
<td>15</td>
</tr>
<tr>
<td></td>
<td>(6 h)</td>
<td>15</td>
</tr>
<tr>
<td>Model group</td>
<td>(3 h)</td>
<td>15</td>
</tr>
<tr>
<td></td>
<td>(6 h)</td>
<td>15</td>
</tr>
<tr>
<td>Baicalin-treated</td>
<td>(3 h)</td>
<td>15</td>
</tr>
<tr>
<td></td>
<td>(6 h)</td>
<td>15</td>
</tr>
<tr>
<td>Octreotide-treated</td>
<td>(3 h)</td>
<td>15</td>
</tr>
<tr>
<td></td>
<td>(6 h)</td>
<td>15</td>
</tr>
<tr>
<td></td>
<td>(12 h)</td>
<td>15</td>
</tr>
</tbody>
</table>

Comparison of plasma endotoxin content

The content was higher in model group and treated group than in sham operation group at all time points (P < 0.001). The content was not different between Baicalin- and octreotide-treated groups at 6 and 12 h. The content was lower in Baicalin- and octreotide-treated groups than in model group at 3 h (P < 0.001), lower in Baicalin-treated group than in model group at 6 h (P < 0.001), lower in octreotide-treated group than in model group at 6 h (P = 0.001), lower in Baicalin-treated group than in model group at 12 h (P < 0.001), and also lower in octreotide-treated group than in model group at 12 h (P < 0.01) (Table 1).
Comparison of serum TNF-α content

Serum TNF-α content in model group and treated groups significantly exceeded sham operation group at different time points (P < 0.001). There was no significant difference among model group, Baicalin-treated group and octreotide-treated group at 3 h and 12 h. At 6 h, serum TNF-α contents in Baicalin-treated group and octreotide-treated group were significantly less than model control group (P < 0.001); and octreotide-treated group had significantly less serum TNF-α content compared to Baicalin-treated group (P < 0.01) (Table 1).

Comparison of serum IL-6 content

Serum IL-6 contents at 3 h and 6 h were significantly higher in model control group and treated groups than in sham operation group (P < 0.001). Baicalin-treated group and octreotide-treated group had no significant difference in serum IL-6 content at all time points.

Table 8  Comparison of Bcl-2 protein in kidney [M (QR)] grade score

<table>
<thead>
<tr>
<th>Groups</th>
<th>3 h</th>
<th>6 h</th>
<th>12 h</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham operation group</td>
<td>0.00 (0.00)</td>
<td>0.00 (0.00)</td>
<td>0.00 (0.00)</td>
</tr>
<tr>
<td>Model group</td>
<td>0.00 (2.00)</td>
<td>3.00 (3.00)</td>
<td>0.00 (1.25)</td>
</tr>
<tr>
<td>Baicalin-treated group</td>
<td>0.00 (0.00)</td>
<td>0.00 (0.00)</td>
<td>0.00 (1.00)</td>
</tr>
<tr>
<td>Octreotide-treated group</td>
<td>0.00 (0.00)</td>
<td>0.00 (0.00)</td>
<td>0.00 (0.00)</td>
</tr>
</tbody>
</table>

Table 9  Apoptotic index of kidney [M (QR)] (%)

<table>
<thead>
<tr>
<th>Groups</th>
<th>3 h</th>
<th>6 h</th>
<th>12 h</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham operation</td>
<td>0.00 (0.00)</td>
<td>0.00 (0.00)</td>
<td>0.00 (0.00)</td>
</tr>
<tr>
<td>Model group</td>
<td>0.00 (0.00)</td>
<td>0.00 (0.00)</td>
<td>0.00 (0.00)</td>
</tr>
<tr>
<td>Baicalin-treated</td>
<td>0.00 (0.01)</td>
<td>0.00 (0.02)</td>
<td>0.00 (0.00)</td>
</tr>
<tr>
<td>Octreotide-treated</td>
<td>0.00 (0.00)</td>
<td>0.00 (0.04)</td>
<td>0.00 (0.00)</td>
</tr>
</tbody>
</table>

Figure 3  Bcl-2 expression in different groups (× 200). A and B: 6-h model group showing high (++) Bcl-2 expression; C: 6-h octreotide-treated group with negative (-) Bcl-2 expression.

Figure 4  Apoptosis in different groups (TUNEL, × 400). A: 6-h octreotide-treated group showing apoptosis of renal tubular epithelial cells; B: 6-h Baicalin-treated group showing apoptosis of renal tubular epithelial cells; C: 6-h model group with no (-) apoptosis; D: 6-h octreotide-treated group showing apoptosis of renal tubular epithelial cells.
and octreotide-treated groups had significantly lower serum IL-6 content compared to model control group at all time points \((P < 0.001)\). The model control group had significantly higher serum IL-6 content than sham operation group at 12 h \((P < 0.001)\), and so was Baicalin-treated group \((P < 0.01)\), but no significant difference was found between octreotide-treated group and sham operation group (Table 1).

**Comparison of serum ET-1 contents**

Serum ET-1 content in model group was significantly higher than in sham operation group at all time points \((P < 0.001)\). At all time points, Baicalin- and octreotide-treated groups had significantly lower serum ET-1 content than model group \((P < 0.001)\). Octreotide-treated group had significantly lower ET-1 content compared to Baicalin-treated group at 3 h and 12 h \((P < 0.01)\). At 3 h, Baicalin-treated group had significantly higher ET-1 content than sham operation group \((P < 0.01)\), but no significant different was found between octreotide-treated group and sham operation group. At 6 h, there was no marked difference between Baicalin-treated group or octreotide-treated group and sham operation group, or between Baicalin-treated group and octreotide-treated group. At 12 h, octreotide-treated group and sham operation group had no marked difference, and Baicalin-treated group had significantly higher ET-1 content than sham operation group \((P < 0.001)\) (Table 1).

**Comparison of correlations among various indexes**

Correlation between apoptotic indexes and Bax and Bcl-2 expression in the kidney: The apoptotic index of Baicalin-treated group at 3 h and that of octreotide-treated group at 3 h and 6 h was positively correlated with Bax expression \((P < 0.001)\). However, there was no correlation between apoptotic index and Bcl-2 expression.

Correlation between pathological score change and BUN and CREA of kidney: The pathological score of sham operation group at 12 h was positively correlated with BUN \((P < 0.01)\) and CREA levels \((P < 0.05)\). The pathological score of model group was positively correlated with CREA at 3 h \((P = 0.01)\) and 6 h \((P < 0.001)\). The score of Baicalin-treated group at 3 h and 6 h was positively correlated with CREA \((P < 0.05)\). The pathological score of Baicalin-treated group at 3 h and 6 h was positively correlated with BUN and CREA \((P < 0.05)\), and that at 6 h and 12 h was positively correlated with CREA \((P < 0.01)\) and BUN \((P < 0.01)\), respectively.

**Correlation analysis among inflammatory mediators:** PLA2 content at 12 h was positively correlated with TNF-\(\alpha\) in model group \((P < 0.05)\), and TNF-\(\alpha\) was positively correlated with PLA2 content \((P < 0.01)\) at 3 h.

**DISCUSSION**

This study demonstrated that there were milder renal pathological changes and lower serum BUN content in treated groups as compared with model group. The survival rate was higher in treated groups compared to model group. All these indicate the potent therapeutic effect of Baicalin and octreotide on rats with severe acute pancreatitis. Baicalin showed superiority over octreotide in decreasing plasma endotoxin and PLA2 content in SAP rats at 3 h, while octreotide was found to be superior to Baicalin in alleviating renal pathological changes and decreasing CREA, Bcl-2, TNF-\(\alpha\), PLA2 (at 12 h) and ET-1 contents.

Regarding the mechanisms via which these two drugs improve renal pathological changes, we mainly hypothesized inhibition of inflammatory mediators and induction of apoptosis.

The endotoxin\(^{[11]}\) in plasma, and PLA2\(^{[12,13]}\), NO\(^{[14,18]}\), TNF-\(\alpha\)\(^{[15,21]}\), IL-6\(^{[21]}\) and ET-1\(^{[22,24]}\) in serum are all important inflammatory mediators during SAP complicated with multiple organ injury. They are important indexes of severity and prognosis of acute pancreatitis and have two important features in common: (1) Dual effects: These inflammatory mediators, especially NO and ET-1, will protect body in low concentration and injure body in high concentration; and (2) There are interactions among different inflammatory mediators. This experiment confirmed a positive correlation between PLA2 and TNF-\(\alpha\). According to many studies as well as our experiment, the concentrations of these inflammatory mediators increase during SAP\(^{[25,31]}\). Our experiment demonstrated that almost all indexes of inflammatory mediators were lower in treated groups than in model group, while the indexes were not different between Baicalin- and octreotide-treated groups, thereby indicating that both drugs, with similar effects, could lower the concentration of inflammatory mediators, inhibit them and protect kidney.

Both necrosis and apoptosis are ways of death of injured cells\(^{[30]}\). In contrast to necrosis, apoptosis does not cause intense inflammatory reaction\(^{[33]}\), while necrosis will cause systemic inflammatory response syndrome\(^{[30]}\). At present, a consensus has been reached on apoptosis of pancreas during SAP\(^{[25,30]}\). When necrosis and apoptosis coexist in pancreas and necrosis prevails, induction of pancreatic apoptosis will result in a protective effect. We believe this conclusion is also applicable to renal apoptosis, which has been demonstrated by this experiment.

This experiment clearly showed that the renal pathological changes were milder in treated group than in model group. The renal apoptotic indexes at 6 h were markedly higher in treated group than in model group. All these indicate the renal pathological changes have been alleviated after apoptosis of renal tubular epithelial cells. In addition, the renal apoptotic indexes were not different between model group and sham operation group, possibly.

---

**Table 10**  Comparison of serum PLA2 content (mean ± SD, U/mL)

<table>
<thead>
<tr>
<th>Groups</th>
<th>3 h</th>
<th>6 h</th>
<th>12 h</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham operation group</td>
<td>14.62 ± 3.02</td>
<td>17.49 ± 3.82</td>
<td>19.02 ± 5.07</td>
</tr>
<tr>
<td>Model group</td>
<td>76.10 ± 16.70</td>
<td>101.46 ± 14.67</td>
<td>105.33 ± 18.10</td>
</tr>
<tr>
<td>Baicalin-treated group</td>
<td>56.25 ± 22.43</td>
<td>67.91 ± 20.61</td>
<td>66.86 ± 22.10</td>
</tr>
<tr>
<td>Octreotide-treated group</td>
<td>74.37 ± 19.94</td>
<td>63.13 ± 26.31</td>
<td>53.63 ± 12.28</td>
</tr>
</tbody>
</table>
because apoptosis had not occurred in model group or its incidence was too low to be detected. The occurrence of apoptosis of renal cells in treated groups, however, demonstrated that both Baicalin and octreotide could induce apoptosis. But some researchers believe the pathological changes would be aggravated by renal apoptosis during SAP[37,38], which is different from our view and therefore worth discussing.

Bax and Bel-2 are two important apoptosis-regulating factors. The homo- or heterodimerization between anti-apoptotic Bel-2 and proapoptotic Bax plays an important role in the apoptosis regulating function of the Bel-2-related proteins. Interestingly, in an excess of Bax, Bax/ Bax homodimers predominate, which promote apoptosis, whereas an excess of Bel-2 leads to the formation of Bel-2/Bax heterodimers, which inhibit apoptosis. Thus, the ratio of Bel-2 to Bax appears to be a critical determinant of a cell’s threshold for undergoing apoptosis. No expression of Bel-2 gene has been found normal pancreatic tissue[39]. In addition, there has been no report on expression of Bel-2 gene in normal renal tissue. It was found in this experiment that the expression levels of both Bax and Bel-2 protein had increased during SAP, possibly because the apoptosis-inducing and -inhibiting factors had been enhanced simultaneously. As a result of the conflict of the two factors, the apoptotic indexes were not different between model group and sham operation group. However, the apoptotic indexes at 6 h were higher in treated group than in sham operation group and model group, indicating that the apoptosis of renal tubular epithelial cells occurred because the apoptosis-inducing factor prevailed in treated group. It was also found that the apoptotic indexes at 3 h were positively correlated with Bax in Baicalin-treated group. The apoptotic indexes at 3 h and 6 h were positively correlated with Bax in octreotide-treated group. But there was no correlation between apoptotic indexes and Bel-2. Thus these data indicate that Bax might have participated in the apoptosis of renal tubular epithelial cells. Compared to model group, the expression level of Bel-2 protein was lower in Baicalin-treated group at 6 h, and in octreotide-treated group at 6 h and 12 h, there by indicating that both Baicalin and octreotide can lower the expression level of Bel-2 protein, enhance the apoptosis-promoting effect of Bax dimer and thereby exert therapeutic effects on SAP. The mechanism of Baicalin- and octreotide-induced renal cell apoptosis may be related to regulation of Bax and Bcl-2 protein expressions. The therapeutic effects and mechanism of Baicalin on SAP rats are similar to those of octreotide.

Background
Up to now, severe acute pancreatitis (SAP) is still an acute clinical disease featuring multiple complications, high morality and difficult treatment. Recent studies found octreotide, a somatostatin analogue, could effectively treat SAP. However, octreotide is expensive, which has hindered its clinical application. Therefore, an important direction of the current study is to find other cheap and effective drugs. Baicalin injection (China National Invention Patent Number ZL200310122673.6) prepared by the first author would be one of the best choice to treat SAP. In this experiment, the feasibility of Baicalin treatment of SAP has been studied by comparing the protecting effects and mechanisms of Baicalin and octreotide on kidneys of rats with SAP.

Applications
Both Baicalin and octreotide can alleviate inflammatory reactions by inhibiting the generation of inflammatory mediators and inducing renal cell apoptosis, and thereby exert therapeutic effects on SAP. The mechanism of Baicalin- and octreotide-induced renal cell apoptosis may be related to regulation of Bax and Bcl-2 protein expressions. The therapeutic effects and mechanism of Baicalin on SAP rats are similar to those of octreotide.

Innovations and breakthroughs
As a cheap medicine with extensive pharmacological actions, few side effects and convenient administration, Baicalin can hopefully become a new drug for treating SAP. The application of tissue microarrays in pathological examination of SAP has several advantages, including time- and energy-saving, high efficiency and good representativeness, and therefore is worth popularizing.

COMMENTS

Research frontiers
Both Baicalin and octreotide can alleviate inflammatory reactions by inhibiting the generation of inflammatory mediators and inducing renal cell apoptosis, and thereby exert therapeutic effects on SAP. The mechanism of Baicalin- and octreotide-induced renal cell apoptosis may be related to regulation of Bax and Bcl-2 protein expressions. The therapeutic effects and mechanism of Baicalin on SAP rats are similar to those of octreotide.

Terminology
Baicalin is an important monomer of Baical skullcap root. Severe acute pancreatitis (SAP) is a fatal systemic disease featuring acute onset, serious conditions, high incidence of complications and 20%-30% of mortality.

Peer review
The authors analyzed the protecting effects and mechanism of Baical skullcap root in the treatment of SAP in rats. The authors showed that Baicalin seems to be equally effective as octreotide in terms of reduction of renal pathological alterations. This study is well performed and the results merit further investigation.

REFERENCES
1. Zhang Q, Ni Q, Cai D. Somastostatin and growth hormone in preventing liver damage due to acute necrotizing pancreatitis Zhonghua Yixue ZaZhi 1998; 78: 621-623


Ding SP, Li JC, Jin C. A mouse model of severe acute pancreatitis induced with caerulein and lipopolysaccharide. World J Gastroenterol 2003; 9: 584-589


Gong L, Xu M. Correlation of cytokines IL-6, IL-8 and TNF-beta levels in peripheral blood with APACHE I score in acute pancreatitis. Zhongguo Yixian Bingue Za Zhi 2003; 3: 23-25


Yao WY, Zha Q, Yan YZ. Tumor Necrosis factor receptor-p55/-p75 gene expression in peripheral blood mononuclear cells in acute pancreatitis in rats. Weichang Bingue Za Zhi 2003; 8: 247-248


Yang YL, Li JP, Li KZ. Tumor necrosis factor alpha antibody prevents brain damage of rats with acute necrotizing pancreatitis. World J Gastroenterol 2004; 10: 2989-2990


Tu WF, Zhu WM, He J, Qi XP, Feng GB, Wu RP, Li JS. Effects of BN50739 on plasma levels of endotoxin and inflammatory mediators in acute severe pancreatitis in pigs. Zhonghua Gandan Waike Za Zhi 2002; 8: 560-563


Chen Q, Shi QL. Application of tissue microarrays technique in lymphoma study. Zhenduan Bingli Xue Za Zhi 2003; 110: 182-184

Yan XC, Duan GJ. Study on tumors by tissue microarrays (tissue chip). Zhonglia Fangzhishi Yanjiu Za Zhi 2003; 30: 519-521


48 **Kipps TJ.** Advances in classification and therapy of indolent B-cell malignancies. *Semin Oncol* 2002; 29: 98-104

49 **Manley S, Mucci NR, De Marzo AM, Rubin MA.** Relational database structure to manage high-density tissue microarray data and images for pathology studies focusing on clinical outcome: the prostate specialized program of research excellence model. *Am J Pathol* 2001; 159: 837-843


S- Editor Zhu LH  L- Editor Kumar M  E- Editor Li JL